Analysis of worldwide surgical outcomes in COVID-19-infected patients: a gynecological oncology perspective.
David L PhelpsSrdjan SasoSadaf Ghaem-MaghamiPublished in: Future science OA (2020)
Coronavirus Disease 2019 (COVID-19) guidance limits all but the most urgent surgery in the United Kingdom. We review the literature and our experience in gynecology to assess perioperative outcomes. PubMed was searched with (surg*[Title])AND(COVID[Title]), (surg*[Title])AND(2019-nCoV[Title]), and (surg*[Title])AND(SARS-CoV-2[Title]), and 67 COVID-19-positive surgical patients across ten hospitals in four countries are included. Median mortality was 33%. Cardiac and pulmonary co-morbidities associated with higher risk of COVID-19-positive postoperative death. Mortality was high in neurosurgery (80%) and the lowest in gynecological oncology surgery (none). This analysis provides an evidence base on which to consider surgical risk assessment for different specialties. Risk of perioperative death needs to be assessed in the context of patients' co-morbidities and surgical specialty. An individualized approach toward surgical decision making is imperative.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- risk assessment
- patients undergoing
- minimally invasive
- decision making
- healthcare
- palliative care
- end stage renal disease
- ejection fraction
- systematic review
- cardiac surgery
- risk factors
- type diabetes
- pulmonary hypertension
- metabolic syndrome
- cardiovascular disease
- left ventricular
- chronic kidney disease
- prognostic factors
- newly diagnosed
- insulin resistance
- skeletal muscle
- patient reported outcomes
- acute kidney injury
- coronary artery disease
- weight loss